Malignant melanoma

• A PK study to compare JPB898 (proposed nivolumab biosimilar) and US-licensed Opdivo® in participants with resected stage IIB, IIC, or III me … Recruiting
  2025-521919-39-00 3 2026-02-10 "Resected stage IIB, IIC, or III melanoma requiring adjuvant "
• A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better than Anti-PD1 Alone in Adult Participants with Resectable Stage 3 or 4 … Recruiting
  2022-502825-17-00 4 2024-10-07 "Melanoma"
• INtra-tumor miCro dosIng in PatIents with advanced malignant mElanoma receiving aNti-PD1 Therapy. A pilot study. Recruiting
  2023-510544-21-00 3 2025-02-18 "Malignant Melanoma"
• Phase 1 Study of IMC-P115C in Advanced PRAME Positive Cancers Recruiting
  2023-509767-25-00 1 2024-11-07 "Advanced PRAME Positive Cancers"
• Early detection of side effects in patients with metastatic melanoma receiving immune checkpoint inhibitor therapy by investigation of the C … Recruiting
  2024-512219-37-00 4 2022-09-06 "melanoma"
• Study of safety and efficacy of DKY709 alone or in combination with PDR001 in patients with advanced solid tumors. Recruitment ended
  2024-513281-19-00 1 2024-11-25 "Nasopharyngeal Carcinoma"
• A Phase 1b, Randomized, Open-Label Trial to Evaluate Safety, Engraftment, and Initial Signs of Clinical Activity of MB097 in Combination wit … Recruitment ended
  2023-507377-17-00 1 2024-08-28 "Advanced Melanoma"
• A phase I, open-label, multi-center study of KFA115 as a single agent and in combination with pembrolizumab in patients with select advanced … Recruitment ended
  2022-502381-25-01 1 2024-03-15 "Thymic Carcinoma"
• A trial to see if the combination of fianlimab with cemiplimab works better than pembrolizumab for preventing or delaying melanoma from com … Recruitment ended
  2022-501576-25-00 5 2023-07-07 "Melanoma"
• Clinical Study of Fianlimab in Combination With Cemiplimab versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated U … Recruitment ended
  2023-505772-30-00 5 2022-11-09 "Melanoma"
• The STARBOARD Study: Phase 3 Study of Encorafenib and Binimetinib Plus Pembrolizumab in BRAF V600E/K Mutation-Positive Metastatic or Unresec … Recruitment ended
  2024-512038-13-00 5 2021-09-16 "Metastatic or unresectable locally advanced BRAF V600E/K mut"
• A Study of PF-08046031 in Adults With Advanced Melanoma and Other Solid Tumors Ended
  2024-514745-10-00 1 2025-06-23 "Melanoma (or) malignant melanoma Non-small cell lung cancer "
• A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DG … Ended
  2023-503996-38-00 1 2025-05-21 "Advanced or metastatic solid tumors"
• Phase 1/2 Study of Cobolimab plus Dostarlimab in Pediatric and Young Adult Participants with Newly Diagnosed and Relapsed/Refractory Tumors Ended
  2024-511350-41-00 9 2025-03-13 "Relapsed/Refractory Tumors"
• A PHASE 2 STUDY EVALUATING INCB099280 IN PARTICIPANTS WITH SELECT SOLID TUMORS WHO ARE IMMUNE CHECKPOINT INHIBITOR–NAÏVE Ended
  2022-502716-37-00 4 2023-11-27 "Recurrent or advanced/metastatic solid tumors who are immuno"
• Phase 2 Study of Encorafenib and Binimetinib Plus Pembrolizumab in Participants With BRAF V600E/K Mutation-Positive Melanoma Who Progressed … Ended
  2023-509471-17-00 4 2023-05-24 "Metastatic or unresectable locally advanced BRAF V600E/K mut"
• A first-in-human clinical trial in adult patients with metastatic or recurrent melanoma of a personalised therapy targeting specific mutatio … Ended
  2024-513062-19-00 7 2022-12-22 "Metastatic or recurrent melanoma"
• A Study to evaluate the Efficacy and Safety of RO7198457 in Combination With Pembrolizumab Versus Pembrolizumab in Patients with Previously … Ended
  2023-507389-15-00 4 2020-02-26 "Advanced Melanoma"
• Safety and efficacy of IMCgp100 versus Investigator’s Choice in advanced uveal melanoma Ended
  2024-517290-24-00 4 2017-12-19 "Previously untreated advanced uveal melanoma (UM)"
• A Phase I Study of INCB099280 in Combination With Ipilimumab in Participants With Selected Solid Tumors Ended
  2023-503243-34-00 3 "Solid tumor"
• Study of the Effectiveness and Safety of Acasunlimab Alone or With Pembrolizumab in treating Advanced Melanoma of the Skin That Has Returned … Ended
  2025-520468-16-00 4 "Cutaneous Melanoma, Relapsed/Refractory, Locally Advanced Un"
• A study of lifileucel (tumor-infiltrating lymphocytes) in adults with advanced melanoma Ended
  2025-522054-40-00 4 "Previously treated advanced melanoma"

Showing 1–22 of 22 trials